Antibiotic Resistance Market Segmented By Drug Class - Beta Lactum Antibiotic | Cephalosporins | Quinolones Antibiotics | Macrolide Antibiotics | Tetracyclines Oxazolidinones
Industry: Healthcare
Published Date: December-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 272
Report ID: PMRREP27895
Worldwide revenue from the antibiotic resistance market stands at US$ 10.1 Bn in 2022, with the global market estimated to surge ahead at a CAGR value of 5.3% to reach a valuation of US$ 17.8 Bn by the end of 2033.
|
Antibiotic Resistance Market Size (2022) |
US$ 10.1 Bn |
|
Projected Market Value (2033) |
US$ 17.8 Bn |
|
Global Market Growth Rate (2023-2033) |
5.3% CAGR |
|
Market Share of Top 4 Countries |
51.4% |
According to Persistence Industry Research, the Beta Lactum antibiotic is anticipated to be worth US$ 821.6 Mn by 2023. Overall, antibiotic resistance market sales account for around 21.0% of the global antibiotic drugs market, which was estimated to be worth approximately US$ 48.2 Bn in 2022.
The global market for antibiotic resistance recorded a historic CAGR of 4.1% in the last 7 years from 2015 to 2022.
Antibiotic resistance (ABR) occurs as a result of inappropriate and uncontrolled antibiotic use. The AMR superbugs includes bacteria, fungi, parasites, and viruses. Antibiotics are available as over-the-counter drugs. Many people take antibiotics without a doctor's prescription. Most clinicians, particularly in developing countries, are given antibiotics for viral illnesses without adequately diagnosing the ailment. Antibiotics were all used to treat COVID patients who developed later on developed co-infections (bacterial with viral).
The pipeline of antibiotic-resistance drugs holds great promise for future treatment possibilities. Many start-ups as well as established players have invested in clinical trials. Community-acquired pneumonia (CAP), which is common, is a major cause of mortality and morbidity throughout Asia Pacific. The Asia-Pacific area is prone to antibiotic-resistant infections due to its large population, aging population, dense urbanization, and limited access to healthcare.
According to recent projections, if AMR is not addressed by 2050, it might result in 10 million deaths per year and global economic expenditures of up to $100 trillion USD. Many impoverished countries may be unable to save enough resources to combat ABR. Access to diagnostics for disease management and self-medication is a major concern throughout the world. One such initiative, the Global Action Plan on ABR, aims to increase the availability of inexpensive antibiotics and support the efficient implementation of this component.
The development of antibiotics is being accelerated due to the entrance of smart technology in the field of medical sciences. Companies like Roche are entering into a multi-year research collaboration with tech companies like Summit therapeutics who has proprietary technology such as the Discuva platform which focused on optimization against bacterial resistance, elucidating mechanisms of action, and also identifying novel targets.
The global antibiotic resistance market is thus likely to show high growth over the coming years a CAGR value of 5.3% and reach a global market size of US$ 17.8 Bn by 2033.
“Prevalence of Drug-resistant infections”
Emerging countries are regarded as a hotspot for the emergence and spread of antimicrobial resistance.
Hospital-acquired diseases and community-acquired pneumonia (CAP) are two of the most common causes of death worldwide. The population is prone to antibiotic-resistant infections due to its enormous size, expanding geriatric population, intensive urbanization, and limited access to health care.
The most common pathogens include Mycoplasma pneumonia, Streptococcus pneumonia, Haemophilus influenza, Staphylococcus aureus, Chlamydophila pneumonia, Haemophilus influenza, and respiratory viruses. However, the presence of Burkholderia pseudomallei and the increased incidence rate of Klebsiella pneumonia are distinct in regions such as Asia-Pacific.
Antibiotic resistance poses a threat to all people globally and this has created the need for antibiotics such as that can counter antibiotic resistance this made manufacturers come up with drugs like Beta Lactum Antibiotic, Cephalosporins, Quinolones Antibiotics, Macrolide Antibiotics, Tetracyclines, Oxazolidinones. The life sciences and healthcare industries should address collaboratively this threat faster.
Big players like Merck & Co. are adding new antibacterial drugs, relebactam which received FDA approval to a previously approved combo of cilastatin and imipenem.
The launch of new pharmaceuticals drugs with regulatory approvals that are accessible and affordable is projected to result in high adoption rates, driving market expansion over the projection period.
“Unaffordable treatment cost in developing regions”
Increasing costs of prescription medicines are obvious, which have become a major public health challenge to healthcare systems in Asia. Accessibility and affordability of costly medicines are two major challenges provoking the global pharmaceutical pricing policy.
It is also stated that medicines are often too expensive for people to afford. As per the WHO, expenditure on treatments and especially medicines accounts for a major proportion of health costs in developing regions. For this reason, access to treatment is strongly dependent on the availability of affordable drugs.
Health care costs in the Asia Pacific have grown up intensely in the past 15 years, rising by 9% yearly compared to the average annual economic growth rate of 6% & in other countries. High R&D costs are often quoted by manufacturers as a reason behind the high costs of their drugs.
Diseases like drug-resistant infections are responsible for prolonged hospital admissions that eventually increase healthcare costs, greater costs in second-line drugs, and overall treatment costs.
Thus, the introduction of alternative treatments and drugs can hamper the antibiotic resistance market.
Why is the U.S. Antibiotic Resistance Market Booming?
“Burden of antibiotic-resistance threats the U.S.”
In 2022, the United States accounted for nearly 89.6% of the North American market, and a similar trend is anticipated over the forecast period.
Antibiotic resistance affects a large number of people in the United States. Each year, with over 2.8 million antibiotic-resistant infections are recorded in the United States, killing over 35,000 individuals. Furthermore, nearly 223,900 patients in the United States needed hospitalization for C. difficile, and also in 2017, at least 12,800 people died.
In partnership with other state and local health departments, federal agencies, patients, public health partners, and the commercial sector, the CDC has taken active action to identify, prevent, and innovate against antibiotic resistance.
CDC conducts U.S. Antibiotic Awareness Week which is dedicated to raising awareness and disseminating information about the necessity of improving antibiotic and antifungal use. Individuals, organizations, and communities are all encouraged to take part in U.S. Antibiotic Awareness Week will be held from November 18 to 24, 2022, with the goal of raising awareness about the significance of enhancing antibiotic and antifungal use and decreasing the development of AR.
As a result of this reimbursement policy on cancer treatment and the rise of the adult population, the involvement of government entities such as the Center for disease control and Prevention (CDC) and others to help raise awareness of antibiotic resistance has increased in the United States, endorsing the value of the overall market.
Will Germany Be a Lucrative Market for Antibiotic Resistance?
“Slowing down its development, saving lives”
Germany held around 21.6% market share of the Europe market in 2022.
The Federal Institute for Drugs and Medical Devices (BfArM) is fighting these resistances at both the national and international levels. The development of novel antibiotics or combinations of active compounds in this field is critical in order to continue adequately treating bacterial illnesses in the future. The Federal Institute of Drugs and Medical Devices (BfArM) concluded in 2022 that around 1200 medications containing systemically active antibiotics are currently approved for human use – however, treating bacterial infectious illnesses remains difficult. Several microorganisms are becoming resistant to antibiotics, and their numbers are increasing.
Combating Antibiotic Resistant Bacteria’s (CARB-X) goal is to accelerate the development of innovative antibiotics and to develop other therapeutics, vaccines, rapid diagnostics, and medical devices to combat drug-resistant bacterial infections.
A supportive environment for development and innovation is enabling Germany to prosper globally becoming the lucrative market for the antibiotic resistance market.
How is Japan Emerging as a Prominent Market for Antibiotic Resistance?
“Favourable Health Policy”
Japan held a market share of about 22.2% of the East Asia market in 2022.
In Japan, the AMR Clinical Reference Centre at the National Centre for Global Health and Medicine estimates that there were approximately 8,000 deaths in 2017 due to bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) and fluoroquinolone-resistant Escherichia coli (FQREC), two of the most common antimicrobial-resistant bacteria.
Since 2016, the Health and Global Policy Institute has sponsored AMR expert sessions. The formation of a neutral discussion platform for businesses, ministries, academics, and the private sector to engage and increase collaboration in order to achieve efficient AMR countermeasures has been a constant demand.
Hence government investments and prevalence are going to drive the Japan market.
Which Drug Class is Widely Adopted in the Global Market?
“Efficiency and effectiveness of Beta-Lactam Antibiotic”
The beta-lactam antibiotic segment held around 25.3% share of the total market in 2022.
Beta-lactam antibiotics were extensively used from the start, and they have received the greatest attention. Beta-lactamases are a unique collection of bacterial enzymes that deconstruct the beta-lactam ring, rendering the beta-lactam antibiotic impotent. These antibiotics are effective against a wide range of anaerobic, gram-positive, and gram-negative bacteria. As a result of the medicine's efficient mechanism and excellent effects, it has become the most often utilized and in-demand drug class in the antibiotic resistance market, propelling the market growth.
Which Pathogen holds the highest market share as a Causative Agent of Antibiotic Resistance?
“Antibiotic Resistance from Staphylococcus aureus”
In 2022, Staphylococcus aureus had the greatest market share of about 19.5% within the global market.
Staphylococcus aureus is naturally resistant to almost every antibiotic known to humankind. Resistance is usually acquired from other sources via horizontal gene transfer; however, chromosomal mutation and antibiotic selection are also necessary. Medication resistance in Staphylococcus aureus can be caused by genetic changes that affect the target DNA gyrase or reduce outer membrane proteins, leading to decreased drug accumulation. As a result, Staphylococcus aureus accounted for the largest share of the market among all pathogens.
Which Disease is common in Antibiotic Resistance?
“Complicated Urinary Tract Infections (CUTI) are growing”
Complicated Urinary Tract Infections (CUTI) is the most common disease, accounting for roughly 19.8% of the global market in 2022.
Most urinary tract infections are caused by rectal and perineal flora colonization of the urogenital tract. The most prevalent organisms are E. coli, Enterococcus, Klebsiella, Pseudomonas, and other Enterococcus or Staphylococcus species. CUTI risk factors include female gender, increasing age, diabetes, obesity, long-term catheters, and frequent intercourse.
Which Mechanism of Action is in demand for Antibiotic Resistance?
“Cell Wall Synthesis Inhibitors are commonly used”
Cell wall synthesis inhibitors held a market share of 36.2% within the global market in 2022.
A number of medications prevent cell wall production. Vancomycin, which inhibits monomer polymerization, and -lactams, such as penicillins and cephalosporins, which inhibit polymer cross-linking, are the most important. Autolysins are activated by -lactam antibacterial drugs. This enables effective results within a short period of time. Hence, cell wall synthesis inhibitors are preferred over others.
Which Distribution Channel Sets be the most lucrative in Antibiotic Resistance Market?
“Easy availability at Hospitals Pharmacies”
Hospitals Pharmacies hold a larger share of about 58.6% with a market value of around US$ 1.78 Bn in 2022. Many times, the doctor's recommended products are not accessible in other places, and even if they are, there is no guarantee of quality. Hospital stores guarantee that the pharmaceuticals are genuine, have not expired, and are reasonably priced. They have the license and authority to sell the drugs and hence this makes them the most lucrative among other segments.
Leading manufacturers are adding technologically advanced items to broaden their product lines around the world. A number of prominent competitors in the antibiotic resistance sector have carried out similar consolidation operations, such as mergers and acquisitions. Another key tactic identified in the business is the rise of firm collaborations to boost their antibiotic resistance offerings. For instance:
|
Attribute |
Details |
|
Forecast Period |
2023-2033 |
|
Historical Data Available for |
2015-2022 |
|
Market Analysis |
USD Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
By Drug Class:
By Pathogen:
By Disease:
By Mechanism of Action:
By Distribution channel:
By Region:
To know more about delivery timeline for this report Contact Sales
The global market is currently valued at around US$ 10.1 Bn in 2022.
Sales of the antibiotic resistance products are set to witness a high growth rate of 5.3% and be valued at US$ 17.8 Bn by 2033.
Demand for the antibiotic resistance market increased at 4.1% CAGR from 2015 to 2022.
The U.S., Australia, Japan, and Germany, account for most demand for antibiotic resistance, currently holding 51.4% market share.
The U.S. accounts for around 89.6% share of the North American market in 2022.
Thermo Fisher Scientific, Inc., Merck KgaA, and Bio-Rad Laboratories, Inc. are the top three manufacturers within this space.
Japan held a market share of about 22.2% of the East Asia market in 2022.
Germany held around 21.6% market share of the Europe market in 2022.
An increased focus on improving drugs, novel drug launches, and favorable regulatory scenarios, are some of the key trends in this market.
The North American region holds a market share of around 31.4% by value in 2022 in the global market.
